Statement: Cohort 1 of the primary trial recorded more optical adversse events than cohort 2.
Primary_evidence: Adverse Events 1:   Total: 61/202 (30.20%)   FEBRILE NEUTROPENIA 1/202 (0.50%)   LEUKOPENIA 0/202 (0.00%)   NEUTROPENIA 2/202 (0.99%)   CARDIAC FAILURE CONGESTIVE 0/202 (0.00%)   CARDIO-RESPIRATORY ARREST 1/202 (0.50%)   PERICARDIAL EFFUSION 1/202 (0.50%)   CATARACT 1/202 (0.50%)   OPTIC NEUROPATHY 0/202 (0.00%)   ABDOMINAL PAIN 0/202 (0.00%)   CONSTIPATION 0/202 (0.00%)   DIARRHOEA 5/202 (2.48%) Adverse Events 2:   Total: 42/201 (20.90%)   FEBRILE NEUTROPENIA 0/201 (0.00%)   LEUKOPENIA 1/201 (0.50%)   NEUTROPENIA 0/201 (0.00%)   CARDIAC FAILURE CONGESTIVE 1/201 (0.50%)   CARDIO-RESPIRATORY ARREST 0/201 (0.00%)   PERICARDIAL EFFUSION 0/201 (0.00%)   CATARACT 1/201 (0.50%)   OPTIC NEUROPATHY 1/201 (0.50%)   ABDOMINAL PAIN 1/201 (0.50%)   CONSTIPATION 1/201 (0.50%)   DIARRHOEA 3/201 (1.49%)